MDMXF (Medmix AG) Notes Receivable: $0.0 Mil (As of Dec. 2025)


MDMXF Medmix AG MDMXF
61 GF Score
Price $17.40
GF Value $26.13
! 7 Warning Signs
View Full Analysis

What is Medmix AG Notes Receivable?

Medmix AG MDMXF 61 Notes Receivable is $0.0 Mil as of Dec. 2025. GuruFocus rates MDMXF with a GF Score™ of 61/100 and a GF Value™ of $26.13. The stock has 7 warning signs investors should review.

Medmix AG's Notes Receivable for the quarter that ended in Dec. 2025 was $0.0 Mil.

Medmix AG Notes Receivable Historical Data

* Premium members only.

The historical data trend for Medmix AG's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medmix AG Notes Receivable Chart

Medmix AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Medmix AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MDMXF
61GF Score
Medmix AG MDMXF
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medmix AG Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.0 Mil mean?
Medmix AG (MDMXF) has a Notes Receivable of $0.0 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Medmix AG and its competitors.
Is Medmix AG's Notes Receivable too high?
Medmix AG's current Notes Receivable is $0.0 Mil. Overall, Medmix AG has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Medmix AG's Notes Receivable compare to GEV and ETN?
Medmix AG's Notes Receivable of $0.0 Mil can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for an Industrial Products company?
A good Notes Receivable depends on the Industrial Products industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Medmix AG and its competitors. Medmix AG's current Notes Receivable is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medmix AG stock overvalued right now?
Medmix AG (MDMXF) has a current Notes Receivable of $0.0 Mil. The stock's GF Value™ is $26.13, compared to a current price of $17.40 — trading 33.4% below its estimated fair value. The current Notes Receivable is $0.0 Mil. Medmix AG's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Medmix AG (MDMXF), the current Notes Receivable is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medmix AG (MDMXF) Overvalued in 2026?

Based on GuruFocus' analysis, Medmix AG stock appears to be undervalued. The current stock price of $17.40 is trading 33.4% below its estimated GF Value™ of $26.13.

Key valuation signals for MDMXF:

  • Notes Receivable: $0.0 Mil
  • GF Value™: $26.13 vs. price of $17.40 (33.4% below fair value)
  • GF Score™: 61/100 with 7 warning signs

No single metric tells the full story. See the MDMXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medmix AG Business Description

Other Exchanges MEDXz:UKMEDX:Switzerland
Address Neuhofstrasse 20, Baar, CHE, 6340
Medmix AG designs and produces high-precision delivery devices for the healthcare, consumer and industrial segments. Its segments are Healthcare, Consumer & Industrial, and Others. The Healthcare segment focuses on delivery devices for the drug delivery, surgery, and dental markets, including injection pens for subcutaneous drug delivery, surgical delivery devices, and mixing and delivery systems for the dental consumable industry. The Consumer & Industrial segment focuses on delivery devices used for industrial applications such as adhesives in construction, electronics, automotive, and aerospace, as well as consumer markets such as beauty and microbrush applications. The company operates in Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
61GF Score

Get the complete analysis for MDMXF

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.40
Price
$26.13
GF Value